CTLA4 and melanoma: In recent years, immune checkpoint inhibitors (ICIs) targeting the programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and programmed cell death receptor 1 (PD-1) have revolutionized the treatment landscape for melanoma (4–7).